Anna M Ferrara

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. ncbi New developments in antibacterial choice for lower respiratory tract infections in elderly patients
    Anna Maria Ferrara
    Department of Haematological, Pneumological, Cardiovascular Medical and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
    Drugs Aging 21:167-86. 2004
  2. ncbi New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance
    A M Ferrara
    Dipartimento di Scienze Ematologiche, Pneumologiche, Cardiovascolari Mediche e Chirurgiche, Sezione di Pneumologia, Padiglione Forlanini, Viale Taramelli 5, 27100 Pavia, Italy
    Infection 33:106-14. 2005
  3. ncbi Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia
    Anna M Ferrara
    Department of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo, Padiglione Forlanini, Viale Taramelli 5, 27100 Pavia, Italy
    Int J Antimicrob Agents 27:183-95. 2006
  4. ncbi Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus
    Anna M Ferrara
    Department of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Taramelli 5, 27100 Pavia, Italy
    Int J Antimicrob Agents 30:19-24. 2007
  5. ncbi A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
    Anna M Ferrara
    Department of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
    Clin Interv Aging 2:179-87. 2007

Detail Information

Publications5

  1. ncbi New developments in antibacterial choice for lower respiratory tract infections in elderly patients
    Anna Maria Ferrara
    Department of Haematological, Pneumological, Cardiovascular Medical and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
    Drugs Aging 21:167-86. 2004
    ..These strategies should be able to reduce the occurrence of risk factors for a poor clinical outcome, hospitalisation and death...
  2. ncbi New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance
    A M Ferrara
    Dipartimento di Scienze Ematologiche, Pneumologiche, Cardiovascolari Mediche e Chirurgiche, Sezione di Pneumologia, Padiglione Forlanini, Viale Taramelli 5, 27100 Pavia, Italy
    Infection 33:106-14. 2005
    ..Finally, a targeted use of these agents will maintain class efficacy...
  3. ncbi Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia
    Anna M Ferrara
    Department of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo, Padiglione Forlanini, Viale Taramelli 5, 27100 Pavia, Italy
    Int J Antimicrob Agents 27:183-95. 2006
    ..aeruginosa. Newer fluoroquinolones and some tetracyclines may be alternative drugs both for MDR S. maltophilia and A. baumannii. However, large-scale controlled clinical trials are needed to confirm these promising therapeutic options...
  4. ncbi Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus
    Anna M Ferrara
    Department of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Taramelli 5, 27100 Pavia, Italy
    Int J Antimicrob Agents 30:19-24. 2007
    ..Other new drugs under development appear to be promising and deserve further evaluation...
  5. ncbi A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
    Anna M Ferrara
    Department of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
    Clin Interv Aging 2:179-87. 2007
    ..In addition, primarily due to a shorter length of hospital stay, moxifloxacin has been shown to save costs compared with standard therapy...